Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.61 |
| ▸ | ST6GAL1 | P15907 | 10/20 | 0.61 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citicoline SCHEMBL4311534 | 1.00 | TSHR (0.76) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL50799 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL31554836 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL31413926 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL221081 | 0.97 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL19347200 | 0.96 | TSHR (0.72) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL21906414 | 0.94 | TSHR (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL667104 | 0.93 | TSHR (0.84) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL13933086 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 | |
| Citicoline SCHEMBL14235352 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | TSHR 1607/4885GLA 4255/4885P2RY2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.